Please login to the form below
Merck and Co.
This page shows the latest Merck and Co. news and features for those working in and with pharma, biotech and healthcare.
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
Merck &Co – known as MSD outside the US and Canada – has highlighted new data for its blockbuster immunotherapy Keytruda used before and after surgery in high-risk, early-stage triple negative ... In March 2021, the US Food and Drug Administration
Latest news
-
Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer
Merck &Co has announced that it will voluntarily withdraw a US Food and Drug Administration (FDA) accelerated approval for Keytruda in third-line stomach cancer. ... In a statement, Merck &Co – known as MSD outside the US and Canada – said that it
-
Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO
AstraZeneca (AZ) and Merck &Co’s PARP inhibitor Lynparza demonstrated positive results in BRCA-mutated high risk early breast cancer, according to new data presented at the 2021 American Society of ... With AZ/Merck &Co already working with regulators
-
Merck & Co spinoff Organon launches with the aim of 'improving health outcomes for women'
Merck &Co – known as MSD outside the US and Canada – announced its plans for the women’s health spinoff company last month. ... Merck &Co spinoff company Organon has launched with the aim of making ‘a better and healthier every day for every
-
New trial data for Keytruda in triple-negative breast cancer
Keytruda plus chemotherapy showed significant and meaningful improvement. Merck &Co – known as MSD outside the US and Canada – has revealed additional data for its blockbuster immunotherapy for high-risk, early-stage ... Although detailed results
-
FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer
The US Food and Drug Administration (FDA) has approved Merck &Co’s Keytruda plus Roche’s Herceptin and chemotherapy in the first-line setting for HER2-positive advanced gastric or gastroesophageal ... line treatment for these patients,” said Roy
More from news
Approximately 44 fully matching, plus 513 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Similarly, Novartis formed the investment firm Novartis Venture Funds and Merck &Co. ... created the Merck Research Venture Fund. Nowadays, having a venture arm to proactively research for outside R&D sourcing is common for most mid- to large- sized
-
AI: the smart money is on the smart thinking
Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... Bayer and Merck &Co hope that radiologists
-
Can protein degraders unlock ‘undruggable’ drug targets?
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
-
Vertex: a vision of treating all CF patients worldwide draws closer
Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.
-
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases? ... The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers
More from intelligence
Approximately 0 fully matching, plus 44 partially matching documents found.
Latest appointments
-
Merck & Co appoints Frank Clyburn as president, human health
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health. ... Clyburn joined Merck &Co in 2008 and during his time with the company, he has had responsibility for various global
-
Weekly industry appointments
Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.
-
Nabriva Therapeutics appoints chief medical officer
Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
-
Hansa Medical poaches Vifor Pharma’s CEO
Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in
-
Astellas promotes Anthony Fiordaliso to VP, Americas finance
He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president
More from appointments
Approximately 4 fully matching, plus 34 partially matching documents found.
Latest from PMHub
-
Practical Patient Centricity
Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.
-
Digital Marketing is no Substitute for Sound Strategic Marketing
With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
B2B media account director
-
Competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- First trial of a vaccine against Alzheimer’s launches
- Merck enters agreement with Hanmi for investigational NASH drug
- Novo Nordisk growth takes a hit with China deal
- Omicron prompts global action
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Sanofi to buy acne specialist Origimm
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- The gold standard of scientific evidence
- AbbVie creates new aesthetics division amid Allergan takeover
- EU approves bluebird bio’s CALD gene therapy Skysona
- Organon buys Forendo in $1bn deal
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
